Chest Radiation May Help Fight Some Advanced Lung Cancers: Study
By Mary Elizabeth Dallas
HealthDay Reporter
MONDAY, Sept. 15, 2014 (HealthDay News) -- Adding chest radiation to chemotherapy allows some people with small-cell lung cancer to live longer and cuts recurrence rates by nearly 50 percent, European researchers report.
Based on the results of a four-country study, the researchers recommended that chest radiotherapy be routinely offered to patients with advanced small-cell lung cancer who respond to chemotherapy.
Small-cell lung cancer (SCLC) is an aggressive form of the disease that accounts for roughly 13 percent of all lung cancers. For most people, the disease spreads to other parts of their body. But chest (thoracic) radiation is not regularly given to patients with small-cell lung cancer, the researchers pointed out.
"Although most SCLC patients have persistent tumors within the chest after chemotherapy, at present local thoracic radiotherapy is not generally given because of the spread of disease outside the thorax, and is reserved for [ease] of symptoms," study author Dr. Ben Slotman, a radiation oncology professor at VU University Medical Center in Amsterdam, said in a news release from The Lancet.
The research was published Sept. 14 in the journal, to coincide with its presentation at the American Society for Radiation Oncology's annual meeting in San Francisco.
"In recent years, we have made some progress in improving survival by giving prophylactic cranial radiotherapy [radiation to the head to reduce the risk of cancer spreading to the brain] after chemotherapy, and this is now considered the standard of care. However, survival for patients with extensive disease remains poor [two-year survival of less than 5 percent] and the likelihood of the cancer recurring and spreading to other parts of the body remains high," Slotman noted.
The study involved 498 adults undergoing chemotherapy at 42 facilities in the Netherlands, the United Kingdom, Norway and Belgium. The patients were randomly assigned to two weeks of standard care with either radiation to the head alone or radiation to the head and chest.
Although survival rates among the two groups of patients was similar during the first year, by the second year, 13 percent of patients who received head and chest radiation had survived, compared to 3 percent of those who received standard therapy.
HealthDay Reporter
MONDAY, Sept. 15, 2014 (HealthDay News) -- Adding chest radiation to chemotherapy allows some people with small-cell lung cancer to live longer and cuts recurrence rates by nearly 50 percent, European researchers report.
Based on the results of a four-country study, the researchers recommended that chest radiotherapy be routinely offered to patients with advanced small-cell lung cancer who respond to chemotherapy.
Small-cell lung cancer (SCLC) is an aggressive form of the disease that accounts for roughly 13 percent of all lung cancers. For most people, the disease spreads to other parts of their body. But chest (thoracic) radiation is not regularly given to patients with small-cell lung cancer, the researchers pointed out.
"Although most SCLC patients have persistent tumors within the chest after chemotherapy, at present local thoracic radiotherapy is not generally given because of the spread of disease outside the thorax, and is reserved for [ease] of symptoms," study author Dr. Ben Slotman, a radiation oncology professor at VU University Medical Center in Amsterdam, said in a news release from The Lancet.
The research was published Sept. 14 in the journal, to coincide with its presentation at the American Society for Radiation Oncology's annual meeting in San Francisco.
"In recent years, we have made some progress in improving survival by giving prophylactic cranial radiotherapy [radiation to the head to reduce the risk of cancer spreading to the brain] after chemotherapy, and this is now considered the standard of care. However, survival for patients with extensive disease remains poor [two-year survival of less than 5 percent] and the likelihood of the cancer recurring and spreading to other parts of the body remains high," Slotman noted.
The study involved 498 adults undergoing chemotherapy at 42 facilities in the Netherlands, the United Kingdom, Norway and Belgium. The patients were randomly assigned to two weeks of standard care with either radiation to the head alone or radiation to the head and chest.
Although survival rates among the two groups of patients was similar during the first year, by the second year, 13 percent of patients who received head and chest radiation had survived, compared to 3 percent of those who received standard therapy.